bulevirtide
bulevirtide: 3 clinical trials tracked.
bulevirtide evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about bulevirtide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 2 study sponsors
Related indications
Clinical Trials (3)
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
Primary endpoint: Proportion of participants with undetectable HDV RNA (<LLOQ Target not detected [TND])
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Primary endpoint: Percentage of participants with a composite endpoint of virologic response and ALT normalization
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)
Primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24